Bio-Artificial Heart as Ultimate Treatment of End-Stage Heart Failure

ABSTRACT: End-stage heart failure is a major health problem, but implementation of guidelines and optimizing medical therapy for this devastating disease should decrease mortality. If optimal conservative therapy is no longer sufficient, a mechanical support system may be required as final destination therapy or as bridge-to-transplant. Since the first heart transplantation in 1967, this therapy has become the criterion standard for end-stage heart failure, but is limited due to organ shortage. Tissue engineering could help overcome this limitation and provide regeneration, remodeling, and growth potential. This so-called bio-artificial heart would be available, created by a decellularized extracellular matrix and seeded with in vitro proliferated autologous cardiovascular cells. Results of the first experimental studies have been promising, but numerous challenges must be met before this procedure will be available.

Keywords: Heart Failure - therapy, Heart Transplantation, Heart, Artificial, Tissue Engineering

References

1. Hunt SA, Abraham WT, Chin MH, 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adult: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation: Circulation, 2009; 119; e391-479, pmid: 19324966

2. McMurray JJV, Adamopoulos S, Anker SD, ESC guidelines for diagnosis and treatment of acute and chronic heart failure 2012: The task force for diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC: Eur Heart J, 2012; 33; 1787-847, pmid: 22611136

3. O’Connell JB, Bristow MR, Economic impact of heart failure in the United States: time for a different approach: J Heart Lung Transplant, 1994; 13; S107-12, pmid: 7947865

4. Rosamond W, Flagal K, Furie KAmerican Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics: 2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Circulation, 2008; 117; e25-e146, pmid: 18086926

5. Costanzo MR, Mills RM, Wynne J, Characteristics of “stage D” heart failure: insights from the Acute Decompensated Heart failure National Registry Longitudinal Module (ADHERE LM): Am Heart J, 2008; 155; 339-47, pmid: 18215606

6. www.herzstiftung.de/herzbericht

7. Friedrich EB, Böhm M, Management of end stage heart failure: Heart, 2007; 93; 626-31, pmid: 17435073

8. Lund LH, Edwards LB, Kucheryavaya AY, The registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report – 2013; focus theme: age: J Heart Lung Transplant, 2013; 32(10); 951-64, pmid: 24054804

9. Ammirati E, Oliva F, Cannata A, Current indications for heart transplantation and left ventricular assist device: A practical point of view: Eur J Intern Med, 2014; 25; 422-29, pmid: 24641806

10. Allen JG, Kilic A, Weiss ES, Should patients 60 years and older undergo bridge to transplantation with continuous-flow left ventricular assist devices?: Ann Thorac Surg, 2012; 94; 2017-24, pmid: 22858277

11. Weiss ES, Allen JG, Patel ND, The impact of donor-recipient sex matching on survival after orthotopic heart transplantation: Analysis of 18 000 transplants in the modern era: Circ Heart Fail, 2009; 2; 401-8, pmid: 19808369

12. Stehlik J, Edwards LB, Kucheryavaya AY, The registry of the International Society for Heart and Lung Transplantation: Twenty-eight adult heart transplantation report – 2011: J Heart Lung Transplant, 2011; 30; 1078-94, pmid: 21962016

13. Slaughter MS, Pagani FD, Rogers JG, Advance heart failure treated with continuous-flow left ventricular assist devices: N Engl J Med, 2009; 361; 2241-51, pmid: 19920051

14. Rose EA, Gelijns AC, Moskowitz AJRandomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group, Long-term use of a left ventricular assist device for end-stage heart failure: N Engl J Med, 2001; 345; 1435-43, pmid: 11794191

15. Schaffer JM, Allen JG, Weiss ES, Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation: J Heart Lung Transplant, 2011; 30; 164-74, pmid: 20888258

16. McIlvennam CK, Allen LA, Nowels C, Decision making for destination therapy left ventricular assist devices: There was no choice versus I thought about it an awful lot: Circ Cardiovasc Qual Outcomes, 2014; 7; 374-80, pmid: 24823949

17. Dohmen PM, Ozaki S, Nitsch R, A tissue engineered heart valve implanted in a juvenile sheep model: Med Sci Monit, 2003; 9(4); BR97-104, pmid: 12709659

18. Brennan MP, Dardik A, Hibino N, Tissue engineered vascular grafts demonstrate evidence of growth when implanted in a juvenile animal model: Ann Surg, 2008; 248; 370-77, pmid: 18791357

19. Dohmen PM, da Costa F, Yoshi S, An experimental study of decellularized xenografts implanted into the aortic position with 4 months of follow up: J Clin Experiement Cardiol, 2012; S4; 004

20. Baraki H, Tudorache I, Braun M, Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model: Biomaterials, 2009; 30; 6240-46, pmid: 19703713

21. Dohmen PM, da Costa F, Lopes SV, Successful implantation of a decellularized equine pericardial patch into the systemic circulation: Med Sci Monit Basic Res, 2014; 20; 1-8, pmid: 24407027

22. Dohmen PM, Konertz W, Tissue engineered heart valve scaffolds: Ann Thorac Cardiovasc Surg, 2009; 15; 362-67, pmid: 20081743

23. Lu TY, Lin Bo, Kim J, Repopulation of decellularized mouse heart with human induced pluripotent stem cell derived cardiovascular progenitor cells: Nat Commun, 2013; 4; 2307, pmid: 23942048

24. Ott HA, Matthiesen TS, Goh SK, Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart: Nat Med, 2008; 14; 213-21, pmid: 18193059

25. Weymann A, Loganathan S, Takahashi H, Development and evaluation of a perfusion decellularization porcine heart model: Circ J, 2011; 75; 852-60, pmid: 21301134

26. Neumann A, Sarikouch S, Breymann T, Early systemic cellular immune response in children and young adults receiving decellularized fresh allografts for pulmonary valve replacement: Tissue Eng Part A, 2014; 20; 1003-11, pmid: 24138470

27. Walles T, Lichtenberg A, Puschmann C: Eur J Cardiothorac Surg, 2003; 24; 358-63, pmid: 12965305

28. Bloch O, Erdbrügger W, Völker W, Extracellular matrix in deoxycholic acid decellularized aortic heart valves: Med Sci Monit, 2012; 18(12); BR487-92, pmid: 23207452

29. Adler CP, Morphological principles of cardiac hypertrophy and heart growth: Med Welt, 1972; 23; 477-84, pmid: 4260533